Renal Pelvis Cancer clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    open to eligible people ages 18 years and up

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

    Los Angeles, California and other locations

Last updated: